Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Suven Life Sciences

AIA Engineering, The Choice Of Ace Stock Pickers



If you are looking for a top-quality stock with a “moat”, you can consider AIA Engineering. A lot of savvy investors have already grabbed the stock

Vineeta Mahnot’s Stock Pick Suven Life Sciences Gives 350% Gain. Is RS Software Next?



Today, Vineeta Mahnot’s followers were thrilled because Suven Life Sciences surged 20% to give overall gains of 350% in just 11 months. RS Software also kept pace with a 12% jump, giving 40% gains since Vineeta’s recommendation a few weeks ago

If You Missed the 300% Gain In Vaibhav Global, You Have Another Chance Now



Vaibhav Global has been a great multi-bagger stock pick of Vineeta Mahnot of Hem Securities. Despite a return of 300% in just 10 months, Vineeta feels the stock has much more value left in it & has recommended a buy

Hem Securities Does It Again With Winning Stock Pick Va-Tech Wabag. Is AIA Engg Next?



Today, when Va-Tech Wabag surged 8% and gave a 30% return since Hem Securities’ recommendation, it became clear that Hem has special stock-picking skills. Now, all eyes are on their latest stock pick AIA Engineering to see whether it will fire as well

Now Even Hem Securities Calls AIA Engg A Potential Multi-Bagger



AIA Engineering is already the favourite of a number of savvy investors. Hem Securities has now joined the elite club and recommended a buy

Is Hem Securities’ Latest Stock Pick Fiem Industries Also A Multibagger?



Hem Securities has been on a roll in the recent past with three of its latest stock picks giving multibagger returns. We analyze their latest stock pick Fiem Industries and see whether it has the potential to enrich investors

Hem Securities Stock Picks Give Super-Duper Multibagger Returns



Hem Securities has hit a purple patch with three of its recent stock picks, Vaibhav Global, Suven Life Science & Tata Elxsi, giving quick fire gains to its lucky shareholders

Hem Securities Stock Pick Suven Life Science Gives 65% Gain In 30 Days



Hem Securities recommended Suven Life Science on 12th October 2012 at Rs. 46. Today, just 30 days later, the stock is at Rs. 78, giving its delirious shareholders a return of 65%. Should investors sell the stock now & cash in on the gains?

Hem Securities Stock Pick Suven Life Science Surges 25%



Hem Securities issued a report on 12th October 2013 in which it identified Suven Life Science as a potential multibagger at the price of Rs. 46. The stock surged 25% to Rs. 57 within a few days. It is now at Rs. 54 giving investors a return of 17%. We explore whether there is more juice left in the stock

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 494 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!